Kronos Bio, Inc.

KRON

US50107A1043

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-21 pm EDT			5-day change	1st Jan Change
1.02 ^USD	-1.92%		+2.05%	-18.40%

May. 09	Earnings Flash (KRON) KRONOS BIO Reports Q1 Revenue $2.52M	MT
May. 09	Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Kronos Bio, Inc. Announces Resignation of Otello Stampacchia from Board of Directors, Effective March 31, 2023

March 27, 2023 at 05:20 pm EDT

Kronos Bio, Inc. announced that Otello Stampacchia, Ph.D., notified company of his decision to resign from board of directors, effective March 31, 2023.

Latest news about Kronos Bio, Inc.

Earnings Flash (KRON) KRONOS BIO Reports Q1 Revenue $2.52M	May. 09	MT
Kronos Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Earnings Flash (KRON) KRONOS BIO Reports Q4 Revenue $2.3M	Mar. 21	MT
Kronos Bio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Kronos Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Kronos Bio, Inc. Announces to Assess KB-0742 At Planned New Dose Schedule in Ongoing Phase 1/2 Study	Mar. 07	CI
Kronos Bio Plans to Reduction in Force	Mar. 07	CI
Kronos Bio Announces Management Shakeup, 3 Top Managers to Step Down in February	Jan. 25	MT
Kronos Bio, Inc. Announces Executive Changes	Jan. 25	CI
Investors got more clues that rate cuts are imminent	Dec. 19
Piper Sandler Trims Price Target on Kronos Bio to $6 From $7, Keeps Overweight Rating	Dec. 19	MT
HC Wainwright Adjusts Price Target on Kronos Bio to $2.50 From $9, Keeps Buy Rating	Dec. 19	MT
Kronos Bio, Inc. Announces Pipeline Update and p300 KAT Inhibitor Development Candidate	Dec. 18	CI
Kronos Bio Insider Bought Shares Worth $1,470,395, According to a Recent SEC Filing	Nov. 17	MT
Earnings Flash (KRON) KRONOS BIO Reports Q3 Revenue $917,000	Nov. 13	MT
Kronos Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
Kronos Bio to Present Positive Preliminary Data from Phase 1 Dose Escalation Portion of Ongoing Phase 1/2 Kb-0742 Study At the Connective Tissue Oncology Society Annual Meeting	23-10-27	CI
Transcript : Kronos Bio, Inc. - Special Call	23-10-13
Kronos Bio, Inc. Presents Positive Preliminary Data from Phase 1 Dose Escalation Portion of Phase 1/2 KB-0742 Study At AACR-NCI-EORTC	23-10-13	CI
Kronos Bio Appoints Sandra Gardiner as Interim Chief Financial Officer	23-09-18	MT
Kronos Bio, Inc. Appoints Sandra A. Gardiner as Interim Chief Financial Officer	23-09-18	CI
Kronos Bio, Inc. Appoints Sandra A. Gardiner as Principal Financial Officer and Principal Accounting Officer	23-09-18	CI
HC Wainwright Adjusts Price Target on Kronos Bio to $9 From $10, Maintains Buy Rating	23-08-21	MT
Kronos Bio Finance Chief Yasir Al-Wakeel Resigning	23-08-17	MT
Kronos Bio Announces Resignation of Yasir Al-Wakeel as Head of Corporate Development, Effective from September 15, 2023	23-08-17	CI

Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Annual Meeting - Abstract No:3102

More about the company

Income Statement Evolution

More financial data

Ratings for Kronos Bio, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.02 USD

Average target price

4.125 USD

Spread / Average Target

+304.41%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
KRONOS BIO, INC.	-18.40%	61.3M
MODERNA, INC.	+44.48%	55.07B
LONZA GROUP AG	+42.89%	40.22B
IQVIA HOLDINGS INC.	-0.86%	41.79B
CELLTRION, INC.	-7.59%	28.17B
ICON PUBLIC LIMITED COMPANY	+12.30%	26.28B
ALNYLAM PHARMACEUTICALS, INC.	-21.83%	18.93B
BIO-TECHNE CORPORATION	+7.15%	13.03B
MEDPACE HOLDINGS, INC.	+29.40%	12.26B
UNITED THERAPEUTICS CORPORATION	+25.15%	12.21B

Other Biotechnology & Medical Research

Kronos Bio, Inc.

Equities

KRON

US50107A1043

Biotechnology & Medical Research

Kronos Bio, Inc. Announces Resignation of Otello Stampacchia from Board of Directors, Effective March 31, 2023

Latest news about Kronos Bio, Inc.

Chart Kronos Bio, Inc.

Company Profile

Income Statement Evolution

Ratings for Kronos Bio, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research